Brian Goodman, PhD Principal, MPM BioImpact Capital

Dr. Brian Goodman is responsible for investment identification, due diligence, business development and new company creation activities at MPM BioImpact Capital. Brian served as the founding Head of Business development at Orna Therapeutics prior to joining the Board of Directors.  Additionally, Brian is a cofounder and head of corporate development and operations at Aktis Therapeutics and serves as a Board Observer of Triplet Therapeutics.

Prior to joining MPM BioImpact, Brian co-founded Evelo Biosciences (EVLO) and served as Head of Technology and Innovation. At Evelo, Brian led a team that established new programs to discover, formulate, and evaluate the pharmacology of microbial drugs across multiple therapeutic areas. He contributed to the in-licensing of foundational IP and forged collaborative research with multiple academic groups to complement Evelo’s internal research and development efforts. He is an inventor on multiple patent applications. Before taking the operational role at Evelo, Brian was a Senior Associate at Flagship Pioneering where he worked with the entrepreneurial division to build and launch new biotech ventures.

Brian holds a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School, and B.S. and B.A. degrees in biochemistry and economics, respectively, from Brandeis University.